Clinical Study of Albendazole Therapy for Strongyloidiasis

Niimura, S; Hirata, Tetsuya; Zaha, Osamu; Nakamura, Hiroshi; A, Kouchi; Uehara, Takeshi; Uechi, Hiroyuki; Ohshiro, Junichi; Shikiya, K; Kinjo, Fukunori

doi:10.11150/kansenshogakuzasshi1970.66.1231

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among other benzimidazole compounds, mebendazole causes a high incidence of liver dysfunction, while albendazole does not provide an adequate eradication effect. [6][7][8][9] A promising new agent, ivermectin, has been recently introduced and shown to be effective against certain nematodes in Japan. Merck, the pharmaceutical company that manufactures this drug, has been supplying it free of charge since 1987 for the treatment of onchocerciasis.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart

Zaha

Hirata

Kinjo

et al. 2002

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart

Zaha

Hirata

Kinjo

et al. 2002

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

“… Naquira 1989 No control group. Nimura 1992 Participants not randomized, no control group. Nontasut 2005 Probably a non‐randomized design.…”

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection

Henriquez-Camacho

Gotuzzo

Echevarría

et al. 2016

Cochrane Database of Systematic Reviews

160

156

View full text Add to dashboard Cite

Background Strongyloidiasis is a gut infection with Strongyloides stercoralis which is common world wide. Chronic infection usually causes a skin rash, vomiting, diarrhoea or constipation, and respiratory problems, and it can be fatal in people with immune deficiency. It may be treated with ivermectin or albendazole or thiabendazole. Objectives To assess the effects of ivermectin versus benzimidazoles (albendazole and thiabendazole) for treating chronic strongyloides infection. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register (24 August 2015); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (January 1966 to August 2015); EMBASE (January 1980 to August 2015); LILACS (August 2015); and reference lists of articles. We also searched the meta Register of Controlled Trials ( m RCT) using 'strongyloid*' as a search term, reference lists, and conference abstracts. Selection criteria Randomized controlled trials of ivermectin versus albendazole or thiabendazole for treating chronic strongyloides infection. Data collection and analysis Two review authors independently extracted data and assessed risk of bias in the included trials. We used risk ratios (RRs) with 95% confidence intervals (CIs) and fixed‐ or random‐effects models. We pooled adverse event data if the trials were sufficiently similar in their adverse event definitions. Main results We included seven trials, enrolling 1147 participants, conducted between 1994 and 2011 in different locations (Africa, Southeast Asia, America and Europe). In trials comparing ivermectin with albendazole, parasitological cure was higher with ivermectin (RR 1.79, 95% CI 1.55 to 2.08; 478 participants, four trials, moderate quality evidence ). There were no statistically significant differences in adverse events (RR 0.80, 95% CI 0.59 to 1.09; 518 participants, four trials, low quality evidence ). In trials comparing ivermectin with thiabendazole, there was little or no difference in parasitological cure (RR 1.07, 95% CI 0.96 to 1.20; 467 participants, three trials, low quality evidence ). However, adverse events were less common with ivermectin (RR 0.31, 95% CI 0.20 to 0.50; 507 participants; three trials, moderate quality evidence ). In trials comparing different dosages of ivermectin, taking a second dose of 200 μg/kg of ivermectin was not associated with higher cure in a small subgroup of participants (RR 1.02, 95% CI 0.94 to 1.11; 94 participants, two trials). Dizziness, nausea, and disorientation were commonly reported in all drug groups. There were no reports of serious adverse events or dea...

show abstract

“…We have used thiabendazole, mebendazole, and albendazole for treatment but believed that ivermectin was the safest drug. [10][11][12] The anthelmintic effect of ivermectin was equivalent to that of thiabendazole. 13 Ivermectin was approved by the Japan …”

Section: Safetymentioning

confidence: 96%

Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody

Zaha

Hirata

Uchima

et al. 2004

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

Clinical Study of Albendazole Therapy for Strongyloidiasis

Cited by 7 publications

References 0 publications

Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart

Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection

Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody

Contact Info

Product

Resources

About